Manhattan Bridge, New York City, USA

Advances in anti-cancer cellular immunotherapy

Friday, September 22nd, 2017
9:00 a.m.
NEOMED Institute (Saint-Laurent)

Confirm my presence

Denis-Claude Roy, M.D., FRCPC

Maisonneuve-Rosemont Hospital, Professor of Medicine, Université de Montréal, Director of Research – East of Montreal, and Scientific director, Centre of Excellence for Cell Therapy, Montréal, Canada

Denis-Claude Roy’s research interests focus on the immunobiology of stem cell transplantation, and particularly at the treatment of cell grafts to foster immunotolerance and develop immune therapies against cancer. He has chaired 15 Phase I-II clinical trials at the national and international level. He has published more than 100 original articles and book chapters in prestigious journals. Dr. Roy is Co-Director of the ThéCell FRSQ Network. He is also CEO of CellCAN Regenerative Medicine and Cell Therapy Network (Network of Centres of Excellence), and CSO of the Centre for Commercialization of Cancer Immunotherapy (C3i). He is currently Director of Research for East-of-Montreal-CIUSSS, and Scientific Director of the Centre of Excellence for Cellular Therapy (CETC), Maisonneuve-Rosemont Hospital.

Denis-Claude Roy received his M.D. degree in 1982 from the Université de Montréal. After completing an Internal Medicine residency and training in Hematology at the Université de Montréal, Dr. Roy did a research fellowship at Harvard University, in the Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston. In 1990, Dr. Roy joined the Division of Hematology and Bone Marrow Transplantation at the Maisonneuve-Rosemont Hospital, Université de Montréal, as Director of the Cell Therapy Laboratory and Clinical Program. He is currently a Full Professor of Medicine at the Université de Montréal.

Share this

Similar Events

© 2017 NEOMED Institute. All Rights Reserved. // Solutions Web Globalia